Study on the Molecular Mechanism of Diarrhea-predominant Irritable Bowel Syndrome With Anxiety and Depression Based on Multi-omics Correlation Analysis

Inclusion Criteria: 1. Meet the Rome IV diagnostic criteria for diarrhea-predominant irritable bowel syndrome; 2. Aged between 18 and 65 years old (inclusive), male or female; 3. HAMA assessment ≥ 14 points or HAMD assessment ≥ 17 points Exclusion Criteria: 1. Patients with severe cardiovascular and cerebrovascular diseases (such as myocardial infarction, cerebral infarction, coronary heart disease, etc.); 2. Abnormal liver and kidney function (ALT or AST \> 1.5 times the upper limit of normal, or T-Bil \> 1.5 times the upper limit of normal, or Cr more than the upper limit of normal), hematopoietic system diseases and tumors; 3. Patients with a history of abdominal surgery (except appendectomy and cholecystectomy); 4. Previous diagnosis of organic diseases of the digestive system, such as inflammatory bowel disease, intestinal tuberculosis, etc., or still associated with peptic ulcer, infectious diarrhea, etc.; 5. Previous diagnosis of diseases similar to irritable bowel syndrome symptoms, such as eosinophilic enteritis, microscopic colitis (including collagen colitis and lymphocytic colitis), lactose intolerance, malabsorption syndrome; 6. Previous diagnosis of non-intestinal digestive system diseases, such as tuberculous peritonitis, gallstones, cirrhosis, chronic pancreatitis; 7. Previous diagnosis of diseases affecting the digestive tract function, such as hyperthyroidism or hypothyroidism, endometriosis, autoimmune diseases, diabetes, etc.; 8. 4\. Patients who have taken drugs with bleeding risk or increased bleeding risk before treatment; 9. 4\. Patients who have taken antidepressant drugs and psychotropic drugs before treatment; 10. 4\. Use drugs that affect gastrointestinal motility and function, such as prokinetic drugs, anticholinergic drugs, calcium channel blockers, 5-HT receptor agonists/antagonists, antidiarrheal agents, antacids, intestinal bacteria modulators and antibiotics; 11. Allergic constitution; 12. Pregnant and lactating women; Others that may affect study compliance or adversely affect the results as judged by the investigator.